Aim. To estimate remote results of Neovasculgen administration in patients with stage II—III chronic lower limbs ischemia due to atherosclerosis obliterans. Material and methods. 6-months open, comparative, prospective, randomized and controlled trial to estimate efficacy and safety of Neovasculgen was performed. 25 of 100 patients were enrolled into control group with standard therapy (pentoxifylline, nicotinic acid, trental, aspirin) and 75 — into clinical group (standard therapy and intramuscular administration of pl-VEGF165). After trial discontinuance 38 patients were under observation during 2.5 years with control examination at 1. 2 and 3 years. Assessment of drug's safety was performed by adverse events recording, laboratory and instrumental examination. Pain-free walking distance was used as primary criterion of efficacy, tissue oxygen tension and ankle-brachial index — as secondary parameters. Results and discussion. Therapeutic effect of pl-VEGF165 was being increased for all follow-up. At 3 years after Neovasculgen administration pain-free walking distance in clinical group increased by 290%. At the same time standard medical therapy was associated with decrease of parameter by 27%. Although favourable result in some patients with stage III chronic ischemia the greatest number of patients had stage II—IIb. Improvement of functional state in clinical group correlated with augmentation of  tissue oxygen tension by 14%. Macrohemodynamics in altered extremity changed insignificantly in both groups. Conclusion. Therapeutic effect of Neovasculgen administration in standard scheme was being increased for 3 years with significant augmentation of pain-free walking distance. The greatest efficacy was observed in patients with stage II—IIb in absence of necrotic changes and need for surgical treatment.